International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 55

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 55

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 55

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

apixabanum

apixaban — 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridine-3-carboxamide

apixaban — 1-(4-méthoxyphényl)-7-oxo-6-[4-(2-oxopipéridin-1-yl)phényl]-4,5,6,7-tétrahydro-1*H*-pyrazolo[3,4-*c*]pyridine-3-carboxamide

apixabán — 1-(4-metoxifenil)-7-oxo-6-[4-(2-oxopiperidin-1-il)fenil]-4,5,6,7-tetrahidro-1*H*-pirazolo[3,4-*c*]piridina-3-carboxamida

$C_{25}H_{25}N_5O_4$



apratastatum

apratastat — (2*S*)-*N*-hydroxy-4-({4-[(4-hydroxybut-2-yn-1-yl)oxy]phenyl]}sulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide

apratastat — (2*S*)-*N*-hydroxy-4-[[4-[(4-hydroxybut-2-ynyl)oxy]phényl]sulfonyl]-2,2-diméthylthiomorpholine-3-carboxamide

apratastat — (2*S*)-*N*-hidroxi-4-({4-[(4-hidroxibut-2-in-1-il)oxi]fenil]}sulfonil)-2,2-dimetiltiomorfolina-3-carboxamida

$C_{17}H_{22}N_2O_6S_2$



arasertaconazolum

arasertaconazole — 1-{(2*R*)-2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1*H*-imidazole

arasertaconazole — (-)-1-[(2*R*)-2-[(7-chloro-1-benzothiophén-3-yl)méthoxy]-2-(2,4-dichlorophényl)éthyl]-1*H*-imidazole

arasertaconazol — 1-{(2*R*)-2-[(7-cloro-1-benzotiofen-3-il)metoxi]-2-(2,4-diclorofenil)etil}-1*H*-imidazol

$C_{20}H_{15}Cl_3N_2OS$



bapineuzumabum

bapineuzumab — immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonal heavy chain), disulfide with human-mouse monoclonal light chain, dimer

bapineuzumab — immunoglobuline G1, anti-(protéine β-amyloïde humaine), dimère du disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal de souris humanisé

bapineuzumab — inmunoglobulina G1, anti-(proteína β-amiloide humana), dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humanizado de ratón

$C_{6466}H_{10018}N_{1734}O_{2026}S_{44}$

brivaracetamum

brivaracetam — (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide

brivaracétam — (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide

brivaracetam — (2*S*)-2-[(4*R*)-2-oxo-4-propilpirrolidin-1-il]butanamida

$C_{11}H_{20}N_2O_2$



caricotamidum

caricotamide	1-(2-amino-2-oxoethyl)-1,4-dihydropyridine-3-carboxamide
caricotamide	1-(2-amino-2-oxoéthyl)-1,4-dihydropyridine-3-carboxamide
caricotamida	1-(2-amino-2-oxoetil)-1,4-dihdropiridina-3-carboxamida

$C_8H_{11}N_3O_2$



catumaxomabum

catumaxomab	immunoglobulin G2a, anti-(human antigen 17-1A) (mouse monoclonal Ho-3/TP-A-01/TPBs01 heavy chain), disulfide with mouse monoclonal Ho-3/TP-A-01/TPBs01 light chain, disulfide with immunoglobulin G2b anti-(human CD3 (antigen)) (rat monoclonal 26/II/6-1.2/TPBs01 heavy chain), bidisulfide with rat monoclonal 26/II/6-1.2/TPBs01 light chain
catumaxomab	hétérodimère entre l'immunoglobuline G2a, anti-(molécule d'adhésion des cellules épithéliales (Ep-CAM) humaine), disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal de souris Ho-3/TP-A-01/TPBs01 (monomère) et l'immunoglobuline G2b, anti-(antigène CD3 humain), disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal de rat 26/II/6-1.2/TPBs01 (monomère)
catumaxomab	heterodímero entre la inmunoglobulina G2a, anti-(molécula de adhesión de las células epiteliales (Ep-CAM) humana), disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal de ratón Ho-3/TP-A-01/TPBs01 (monómero) y la inmunoglobulina G2b, anti-(antígeno CD3 humano), disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal de rata 26/II/6-1.2/TPBs01 (monómero)

dapiclerminum

dapiclermin	[17-alanine,63-arginine]ciliary neurotrophic factor-(2-185)-peptide (human)
dapiclermine	[17-alanine,63-arginine]facteur neurotrophique ciliaire humain-(2-185)-peptide
dapiclermina	[17-alanina ,63-arginina]factor neurotrófico ciliar humano-(2-185)-péptido

$C_{945}H_{1482}N_{266}O_{278}S_3$

AFTEHSPLT PHRRDLASRS IWLARKIRSD LTALTESYVK
HQGLNKNINL DSADGMPVAS TDRWSELTEA ERLQENLQAY
RTFHVLLARL LEDQQVHFTP TEGDFHQAIH TLLLQVAAFA
YQIEELMILL EYKIPRNEAD GMPINVGDGG LFEKKLWGLK
VLQELSQWTV RSIHDLRFIS SHQTG

dexlansoprazolum

dexlansoprazole — (+)-2-[(*R*)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}= sulfinyl]-1*H*-benzamidazole

dexlansoprazole — (+)-2-[(*R*)-[[3-méthyl-4-(2,2,2-trifluoroéthoxy)pyridin-2-yl]méthyl]= sulfinyl]-1*H*-benzimidazole

dexlansoprazol — (+)-2-[(*R*)-[[3-metil-4-(2,2,2-trifluoroetoxi)piridin-2-il]metil]sulfinil]-1*H*-benzoimidazol

$C_{16}H_{14}F_3N_3O_2S$



dianiclinum

dianicline — (5a*S*,8*S*,10a*R*)-6,7,9,10-tetrahydro-5a*H*,11*H*-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-*d*]azepine

dianicline — (-)-(5a*S*,10a*R*)-6,7,9,10-tétrahydro-5a*H*,11*H*-8,10a-méthanopyrido[2',3':5,6]pyrano[2,3-*d*]azépine

dianiclina — (5a*S*,8*S*,10a*R*)-6,7,9,10-tetrahidro-5a*H*,11*H*-8,10a-metanopirido[2',3':5,6]pirano[2,3-*d*]azepina

$C_{13}H_{16}N_2O$



ecallantidum

ecallantide — [Glu[20],Ala[21],Arg[36],Ala[38],His[39],Pro[40],Trp[42]]tissue factor pathway inhibitor (human)-(20-79)-peptide (modified on reactive bond region Kunitz inhibitor 1 domain containing fragment)

écallantide — [Glu[20],Ala[21],Arg[36],Ala[38],His[39],Pro[40],Trp[42]]inhibiteur de la voie du facteur tissulaire humain-(20-79)-peptide (fragment du TFPI contenant le domaine de type Kunitz 1modifié au niveau de sa boucle réactive)

ecalantida — [Glu[20],Ala[21],Arg[36],Ala[38],His[39],Pro[40],Trp[42]]inhibidor de la vía del factor tisular humano-(20-79)-péptido (fragmento del TFPI que contiene el dominio de tipo Kunitz 1 modificado en su región reactiva)

$C_{305}H_{442}N_{88}O_{91}S_8$

```
                              E AMHSFCAFKA DDGPCRAAHP
RWFFNIFTRQ CEEFIYGGCE GNQNRFESLE ECKKMCTRD
```

ertumaxomabum

ertumaxomab	immunoglobulin G2a, anti-(human neu (receptor)) (mouse monoclonal 2502A/TP-A-02/TPBs03 heavy chain), disulfide with mouse monoclonal 2502A/TP-A-02/TPBs03 light chain, disulfide with immunoglobulin G2b anti-(human CD3 (antigen)) (rat monoclonal 26/II/6-1.2/TPBs03 heavy chain), bidisulfide with rat monoclonal 26/II/6-1.2/TPBs03 light chain
ertumaxomab	hétérodimère entre l'immunoglobuline G2a, anti-(récepteur erbB-2 tyrosine protéine kinase (HER2, NEU) humain), disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal de souris 2502A/TP-A-02/TPBs03 (monomère) et l'immunoglobuline G2b, anti-(antigène CD3 humain), disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal de rat 26/II/6-1.2/TPBs03 (monomère)
ertumaxomab	heterodímero entre la inmunoglobulina G2a, anti-(receptor erbB-2 tirosina proteína kinasa (HER2, NEU) humano), disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal de ratón 2502A/TP-A-02/TPBs03 (monómero) y la inmunoglobulina G2b, anti-(antígeno CD3 humano), disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal de rata 26/II/6-1.2/TPBs03 (monómero)

esmirtazapinum

esmirtazapine	(14b*S*)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-*a*]pyrido=[2,3-*c*][2]benzazepine
esmirtazapine	(+)-(14b*S*)-2-méthyl-1,2,3,4,10,14b-hexahydropyrazino=[2,1-*a*]pyrido[2,3-*c*][2]benzazépine
esmirtazapina	(14b*S*)-2-metil-1,2,3,4,10,14b-hexahidropirazino[2,1-*a*]pirido=[2,3-*c*][2]benzazepina

$C_{17}H_{19}N_3$



fosfluridinum tidoxilum

fosfluridine tidoxil	5-fluorouridine 5'-[(2*RS*)-2-(decyloxy)-3-(dodecylsulfanyl)propyl hydrogen phosphate]
fosfluridine tidoxil	hydrogénophosphate de (2*RS*)-2-(décyloxy)-3-(dodécylsulfanyl)=propyle et de [(2*R*,3*S*,4*R*,5*R*)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-3,4-dihydroxytétrahydrofuran-2-yl]méthyle
fosfluridina tidoxilo	5-fluorouridina 5'-[(2*RS*)-2-(deciloxi)-3-(dodecilsulfanil)propil hidrógeno fosfato]

$C_{34}H_{62}FN_2O_{10}PS$



isproniclinum

ispronicline (2*S*,4*E*)-*N*-methyl-5-{5-[(propan-2-yl)oxy]pyridin-3-yl}pent-4-en-2-amine

ispronicline (2*S*,4*E*)-*N*-méthyl-5-[5-(1-méthyléthoxy)pyridin-3-yl]pent-4-én-2-amine

isproniclina (2*S*,4*E*)-*N*-metil-5-{5-[(propan-2-il)oxi]piridin-3-il}pent-4-en-2-amina

$C_{14}H_{22}N_2O$



istaroximum

istaroxime 3-[(2-aminoethoxy)imino]-5α-androstan-6,17-dione

istaroxime 3-[(2-aminoéthoxy)imino]-5α-androstane-6,17-dione

istaroxima 3-[(2-aminoetoxi)imino]-5α-androstano-6,17-diona

$C_{21}H_{32}N_2O_3$



lecozotanum

lecozotan 4-cyano-*N*-{(2*R*)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl}-*N*-(pyridin-2-yl)benzamide

lécozotan (+)-4-cyano-*N*-[(2*R*)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)pipérazin-1-yl]propyl]-*N*-(pyridin-2-yl)benzamide

lecozotán 4-ciano-*N*-{(2*R*)-2-[4-(2,3-dihidro-1,4-benzodioxin-5-il)piperazin-1-il]propil}-*N*-(piridin-2-il)benzamida

$C_{28}H_{29}N_5O_3$



levolansoprazolum

levolansoprazole	(-)-2-[(*S*)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}= sulfinyl]-1*H*-benzamidazole
lévolansoprazole	(-)-2-[(*S*)-[[3-méthyl-4-(2,2,2-trifluoroéthoxy)pyridin-2-yl]méthyl]= sulfinyl]-1*H*-benzimidazole
levolansoprazol	(-)-2-[(*S*)-{[3-metil-4-(2,2,2-trifluoroetoxi)piridin-2-il]metil}sulfinil]-1*H*-benzoimidazol

$C_{16}H_{14}F_3N_3O_2S$



manitimusum

manitimus	(2*Z*)-2-cyano-3-hydroxy-*N*-[4-(trifluoromethyl)phenyl]hept-2-en-6-ynamide
manitimus	(2*Z*)-2-cyano-3-hydroxy-*N*-[4-(trifluorométhyl)phényl]hept-2-én-6-ynamide
manitimús	(2*Z*)-2-ciano-3-hidroxi-*N*-[4-(trifluorometil)fenil]hept-2-en-6-inamida

$C_{15}H_{11}F_3N_2O_2$



mapatumumabum

mapatumumab	immunoglobulin G1, anti-(human cytokine receptor DR4 (death receptor 4))(human monoclonal TRM-1 heavy chain), disulfide with human monoclonal TRM-1 λ-chain, dimer
mapatumumab	immunoglobuline G1, anti-(élément 10A humain dans la « superfamille » du récepteur du facteur de nécrose tumorale (récepteur DR4)), dimère du disulfure entre la chaîne lourde et la chaîne λ de l'anticorps monoclonal humain TRM-1
mapatumumab	inmunoglobulina G1, anti-(elemento 10A humano de la « superfamilia » del receptor del factor de necrosis tumoral (receptor DR4)), dímero del disulfuro entre la cadena pesada y la cadena λ del anticuerpo monoclonal humano TRM-1

$C_{6748}H_{10408}N_{1800}O_{2092}S_{52}$

nebicaponum

nebicapone	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethan-1-one
nébicapone	1-(3,4-dihydroxy-5-nitrophényl)-2-phényléthanone
nebicapone	1-(3,4-dihidroxi-5-nitrofenil)-2-feniletan-1-ona

$C_{14}H_{11}NO_5$



nerispirdinum

nerispirdine	*N*-(3-fluoropyridin-4-yl)-3-methyl-*N*-propyl-1*H*-indol-1-amine
nérispirdine	*N*-(3-fluoropyridin-4-yl)-3-méthyl-*N*-propyl-1*H*-indol-1-amine
nerispirdina	*N*-(3-fluoroparidin-4-il)-3-metil-*N*-propil-1*H*-indol-1-amina

$C_{17}H_{18}FN_3$



ofatumumabum

ofatumumab — immunoglobulin G1, anti-(human CD20 (antigen))(human monoclonal HuMax-CD20 heavy chain), disulfide with human monoclonal HuMax-CD20 κ-chain, dimer

ofatumumab — immunoglobuline G1, anti-(antigène CD20 humain), dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal humain HuMax-CD20

ofatumumab — inmunoglobulina G1, anti-(antígeno CD20 humano), dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal humano HuMax-CD20

$C_{6480}H_{10022}N_{1742}O_{2020}S_{44}$

olmesartanum

olmesartan — 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl}-1*H*-imidazole-5-carboxylic acid

olmésartan — acide 4-(1-hydroxy-1-méthyléthyl)-2-propyl-1-[[2'-(1*H*-tétrazol-5-yl)=biphényl-4-yl]méthyl]-1*H*-imidazole-5-carboxylique

olmesartán — ácido 4-(2-hidroxipropan-2-il)-2-propil-1-{[2'-(1*H*-tetrazol-5-il)bifenil-4-il]metil}-1*H*-imidazol-5-carboxílico

$C_{24}H_{26}N_6O_3$



padoporfinum

padoporfin — {hydrogen 3-[(2^2*R*,7*R*,8*R*,17*S*,18*S*)-12-acetyl-7-ethyl-2^2-(methoxycarbonyl)-3,8,13,17-tetramethyl-2^1-oxo-2^1,2^2,7,8,17,18-hexahydrocyclopenta[*at*]porphorin-18-yl]propanoato-κ4*N*^{21},*N*^{22},*N*^{23},*N*^{24}}palladium

padoporfine — (*SP*-4-2)-[hydrogéno-3-[(2^2*R*,7*R*,8*R*,17*S*,18*S*)-12-acétyl-7-éthyl-2^2-(méthoxycarbonyl)-3,8,13,17-tétraméthyl-2^1-oxo-2^1,2^2,7,8,17,18-hexahydrocyclopenta[*at*]porphyrin-18-yl]propanoato-κ*N*^{21},κ*N*^{22},κ*N*^{23},κ*N*^{24}]palladium

padoporfina — (*SP*-4-2)-[hidrógeno-3-[(2^2*R*,7*R*,8*R*,17*S*,18*S*)-12-acetil-7-etil-2^2-(metoxicarbonil)-3,8,13,17-tetrametil-2^1-oxo-2^1,2^2,7,8,17,18-hexahidrociclopenta[*at*]porfirin-18-il]propanoato-κ*N*^{21},κ*N*^{22},κ*N*^{23},κ*N*^{24}]paladio

$C_{35}H_{36}N_4O_6Pd$



pagibaximabum

pagibaximab	immunoglobulin G1, anti-(*Staphylococcus epidermidis* lipoteichoic acid)(human-mouse monoclonal heavy chain), disulfide with human-mouse monoclonal κ-chain, dimer
pagibaximab	immunoglobuline G1, anti-(acide lipotéichoïque *Staphylococcus epidermis*), dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal chimérique homme-souris
pagibaximab	inmunoglobulina G1, anti-(ácido lipoteicoico de *Staphylococcus epidermis*), dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal quimérico hombre-ratón

$C_{6462}H_{9996}N_{1728}O_{2028}S_{54}$

palirodenum

paliroden	1-[2-(biphenyl-4-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
palirodène	1-[2-(biphényl-4-yl)éthyl]-4-[3-(trifluorométhyl)phényl]-1,2,3,6-tétrahydropyridine
palirodeno	1-[2-(bifenil-4-il)etil]-4-[3-(trifluorometil)fenil]-1,2,3,6-tetrahidropiridina

$C_{26}H_{24}F_3N$



peforelinum

peforelin	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-histidyl-L-α–asparagyl-L-tryptophyl-L-lysyl-L-prolylglycinamide
péforéline	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-séryl-L-histidyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-prolylglycinamide
peforelina	5-oxo-L-prolil-L-histidil-L-triptofil-L-seril-L-histidil-L-α-asparagil-L-triptofil-L-lisil-L-prolilglicinamida

$C_{59}H_{74}N_{18}O_{14}$



plerixaforum

plerixafor — 1,1'-(1,4-phenylenebismethylene)bis(1,4,8,11-tetraazacyclotetradecane)

plérixafor — 1,1'-(1,4-phénylènebisméthylène)bis(1,4,8,11-tétraazacyclotétradécane)

plerixafor — 1,1'-(1,4-fenilenobismetileno)bis(1,4,8,11-tetraazaciclotetradecano)

$C_{28}H_{54}N_8$



plitidepsinum

plitidepsin — 3,6-anhydro(*N*-{(2*S*,4*S*)-4-[(3*S*,4*R*,5*S*)-3-hydroxy-4-{[*N*-(2-oxopropanoyl)-L-prolyl-*N*-methyl-D-leucyl-L-threonyl]amino}-5-methylheptanoyloxy]-2,5-dimethyl-3-oxohexanoyl}-L-leucyl-L-prolyl-*N*,*O*-dimethyl-L-tyrosine)

plitidepsine — (-)-(3*S*,6*R*,7*S*,10*R*,11*S*,15*S*,17*S*,20*S*,25a*S*)-11-hydroxy-3-(4-méthoxybenzyl)-2,6,17-triméthyl-15-(1-méthyléthyl)-7-[[(2*R*)-4-méthyl-2-[méthyl[[(2*S*)-1-(2-oxopropanoyl)pyrrolidin-2-yl]carbonyl]amino]pentanoyl]amino]-10-[(1*S*)-1-méthylpropyl]-20-(2-méthylpropyl)tétradécahydro-15*H*-pyrrolo[2,1-*f*]=[1,15,4,7,10,20]dioxatétrazacyclotricosine-1,4,8,13,16,18,21(17*H*)-heptone

plitidepsina — 3,6-anhidro(*N*-{(2*S*,4*S*)-4-[(3*S*,4*R*,5*S*)-3-hidroxi-4-{[*N*-(2-oxopropanoil)-L-prolil-*N*-metil-D-leucil-L-treonil]amino}-5-metilheptanoiloxi]-2,5-dimetil-3-oxohexanoil}-L-leucil-L-prolil-*N*,*O*-dimetil-L-tirosina)

$C_{57}H_{87}N_7O_{15}$



pradefovirum

pradefovir	(2*R*,4*S*)-2-{[2-(6-amino-9*H*-purin-9-yl)ethoxy]methyl}-4-(3-chlorophenyl)-1,3,2λ^5-dioxaphosphinan-2-one
pradéfovir	(2*R*,4*S*)-2-[[2-(6-amino-9*H*-purin-9-yl)éthoxy]méthyl]-4-(3-chlorophényl)-1,3,2λ^5-dioxaphosphinan-2-one
pradefovir	(2*R*,4*S*)-2-{[2-(6-amino-9*H*-purin-9-il)etoxi]metil}-4-(3-clorofenil)-1,3,2λ^5-dioxafosfinan-2-ona

$C_{17}H_{19}ClN_5O_4P$



radequinilum

radequinil	5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1*H*)-one
radéquinil	5-(3-méthoxyphényl)-3-(5-méthyl-1,2,4-oxadiazol-3-yl)-1,6-naphtyridin-2(1*H*)-one
radequinilo	5-(3-metoxifenil)-3-(5-metil-1,2,4-oxadiazol-3-il)-1,6-naftiridin-2(1*H*)-ona

$C_{18}H_{14}N_4O_3$



rimacalibum

rimacalib — *N*-{3-[(1*S*)-1-(2-fluorobiphenyl-4-yl)ethyl]-1,2-oxazol-5-yl}morpholine-4-carboximidamide

rimacalib — (+)-*N*-[3-[(1*S*)-1-(2-fluorobiphényl-4-yl)éthyl]isoxazol-5-yl]morpholine-4-carboximidamide

rimacalib — *N*-{3-[(1*S*)-1-(2-fluorobifenil-4-il)etil]-1,2-oxazol-5-il}morfolina-4-carboximidamida

$C_{22}H_{23}FN_4O_2$



rivaniclinum

rivanicline — (3*E*)-*N*-methyl-4-(pyridin-3-yl)but-3-en-1-amine

rivanicline — (3*E*)-*N*-méthyl-4-(pyridin-3-yl)but-3-én-1-amine

rivaniclina — ácido (3*E*)-*N*-metil-4-(piridin-3-il)but-3-en-1-amina

$C_{10}H_{14}N_2$



rivenprostum

rivenprost — methyl 4-({2-[(1*R*,2*R*,3*R*)-3-hydroxy-2-{(1*E*,3*S*)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-en-1-yl}-5-oxocyclopentyl]0 ethyl}sulfanyl)butanoate

rivenprost — 4-[[2-[(1*R*,2*R*,3*R*)-3-hydroxy-2-[(1*E*,3*S*)-3-hydroxy-4-[3-(méthoxyméthyl)phényl]but-1-ényl]-5-oxocyclopentyl]= éthyl]sulfanyl]butanoate de méthyle

rivenprost — 4-({2-[(1*R*,2*R*,3*R*)-3-hidroxi-2-{(1*E*,3*S*)-3-hidroxi-4-[3-(metoximetil)= fenil]but-1-en-1-il}-5-oxociclopentil]etil}sulfanil)butanoato de metilo

$C_{24}H_{34}O_6S$



satavaptanum

satavaptan — N-*tert*-butyl-4-({cis-5'-ethoxy-4-[2-(morpholin-4-yl)ethoxy)]-2'-oxo-1',2'-dihydrospiro[cyclohexane-1:3'-indole]-1'-yl}sulfonyl)-3-methoxybenzamide

satavaptan — *N*-(1,1-diméthyléthyl)-4-[[*cis*-5'-éthoxy-4-[2-(morpholin-4-yl)éthoxy]-2'-oxospiro[cyclohexane-1,3'-[3*H*]indol]-1'(2'*H*)-yl]sulfonyl]-3-méthoxybenzamide

satavaptán — *N-terc*-butil-4-({*cis*--5'-etoxi-4-[2-(morfolin-4-il)etoxi)]-2'-oxo-1',2'-dihidrospiro[ciclohexano-1:3'-indol]-1'-il}sulfonil)-3-metoxibenzamida

$C_{33}H_{45}N_3O_8S$



seletracetamum

seletracetam — (2*S*)-2-[(4*S*)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide

sélétracétam — (2*S*)-2-[(4*S*)-4-(2,2-difluoroéthényl)-2-oxopyrrolidin-1-yl]butanamide

seletracetam — (2*S*)-2-[(4*S*)-4-(2,2-difluoroetenil)-2-oxopirrolidin-1-il]butanamida

$C_{10}H_{14}F_2N_2O_2$



sipoglitazarum

sipoglitazar — 3-(3-ethoxy-1-{4-[(2-phenyl-1,3-thiazol-4-yl)methoxy]benzyl}-1*H*-pyrazol-4-yl)propanoic acid

sipoglitazar — acide 3-[3-éthoxy-1-[4-[(2-phénylthiazol-4-yl)méthoxy]benzyl]-1*H*-pyrazol-4-yl]propanoïque

sipoglitazar — ácido 3-(3-etoxi-1-{4-[(2-fenil-1,3-tiazol-4-il)metoxi]bencil}-1*H*-pirazol-4-il)propanoico

$C_{25}H_{25}N_3O_4S$



sunitinibum

sunitinib — *N*-[2-(diethylamino)ethyl]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene)methyl]-2,4-dimethyl-1*H*-pyrrole-3-carboxamide

sunitinib — *N*-[2-(diéthylamino)éthyl]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène)méthyl]-2,4-diméthyl-1*H*-pyrrole-3-carboxamide

sunitinib — *N*-[2-(dietilamino)etil]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihidro-3*H*-indol-3-ilideno)metil]-2,4-dimetil-1*H*-pirrol-3-carboxamida

$C_{22}H_{27}FN_4O_2$



surinabantum

surinabant — 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-*N*-(piperidin-1-yl)-1*H*-pyrazole-3-carboxamide

surinabant — 5-(4-bromophényl)-1-(2,4-dichlorophényl)-4-éthyl-*N*-(pipéridin-1-yl)-1*H*-pyrazole-3-carboxamide

surinabant — 5-(4-bromofenil)-1-(2,4-diclorofenil)-4-etil-*N*-(piperidin-1-il)-1*H*-pirazol-3-carboxamida

$C_{23}H_{23}BrCl_2N_4O$



tasidotinum

tasidotin — *N*,*N*-dimethyl-L-valyl-L-valyl-*N*-methyl-L-valyl-L-prolyl-*N*-(*tert*-butyl)-L-prolinamide

tasidotine — *N*,*N*-diméthyl-L-valyl-L-valyl-*N*-méthyl-L-valyl-L-prolyl-*N*-(1,1-diméthyléthyl)-L-prolinamide

tasidotina — *N*,*N*-dimetil-L-valil-L-valil-*N*-metil-L-valil-L-prolil-N-(*terc*-butil)-L-prolinamida

$C_{32}H_{58}N_6O_5$



tasquinimodum

tasquinimod — 4-hydroxy-5-methoxy-*N*,1-dimethyl-2-oxo-*N*-[4-(trifluoromethyl)= phenyl]-1,2-dihydroquinoline-3-carboxamide

tasquinimod — 4-hydroxy-5-méthoxy-*N*,1-diméthyl-2-oxo-*N*-[4-(trifluorométhyl)= phényl]-1,2-dihydroquinoléine-3-carboxamide

tasquinimod — 4-hidroxi- *N*,1-dimetil 5-metoxi-*N*-[4-(trifluorometil)fenil]-2-oxo-1,2-dihidroquinolina-3-carboxamida

$C_{20}H_{17}F_3N_2O_4$



terutrobanum

terutroban — 3-[(6*R*)-6-(4-chlorobenzenesulfonamido)-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid

térutroban — acide 3-[(6*R*)-6-[[(4-chlorophényl)sulfonyl]amino]-2-méthyl-5,6,7,8-tétrahydronaphtalén-1-yl]propanoïque

terutrobán — ácido 3-[(6*R*)-6-(4-clorobencenosulfonamido)-2-metil-5,6,7,8-tetrahidronaftalen-1-il]propanoico

$C_{20}H_{22}ClNO_4S$



tesetaxelum

tesetaxel — 2'-[(dimethylamino)methyl]-1-hydroxy-5β,20-epoxy-9α,10α-dihydro[1,3]dioxolo[4',5':9,10]tax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2*R*,3*S*)-3-[(*tert*-butoxycarbonyl)amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoate}

tésétaxel — (-)-2a-acétate, 3-benzoate et 6-[(2*R*,3*S*)-3-[[(1,1-diméthyléthoxy)= carbonyl]amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoate] de (2a*S*,2b*R*,3*S*,4*S*,6*S*,8a*R*,10*S*,11a*S*,11b*R*,13a*R*)-10-[(diméthylamino)méthyl]-4-hydroxy-7,11b,14,14-tétraméthyl-3,4,5,6,8a,11a,11b,12,13,13a-décahydro-4,8-méthano-2*H*-oxéto[3'',2'':3',4']benzo[1',2':3,4]cyclodéca[1,2-*d*][1,3]dioxol-2a,3,6(2b*H*)-triyle

tesetaxel — 2'-[(dimetilamino)metil]-1-hidroxi-5β,20-epoxi-9α,10α-dihidro[1,3]dioxolo[4',5':9,10]tax-11-eno-2α,4,13α-triil 4-acetato 2-benzoato 13-{(2*R*,3*S*)-3-[(*terc*-butoxicarbonil)amino]-3-(3-fluoropiridin-2-il)-2-hidroxipropanoato}

$C_{46}H_{60}FN_3O_{13}$



tretazicarum

tretazicar — 5-(aziridin-1-yl)-2,4-dinitrobenzamide

trétazicar — 5-(aziridin-1-yl)-2,4-dinitrobenzamide

tretazicar — 5-(aziridin-1-il)-2,4-dinitrobenzamida

$C_9H_8N_4O_5$



udenafilum

udenafil — 3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)-*N*-{2-[(2*RS*)-1-methylpyrrolidin-2-yl]ethyl}-4-propoxybenzenesulfonamide

udénafil — 3-(1-méthyl-7-oxo-3-propyl-4,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)-*N*-[2-[(2*RS*)-1-méthylpyrrolidin-2-yl]éthyl]-4-propoxybenzènesulfonamide

udenafilo — 3-(1-metil-7-oxo-3-propil-4,7-dihidro-1*H*-pirazolo[4,3-*d*]pirimidin-5-il)-*N*-{2-[(2*RS*)-1-metilpirrolidin-2-il]etil}-4-propoxibencenosulfonamida

$C_{25}H_{36}N_6O_4S$



and enantiomer
et énantiomère
y enantiómero

valategrastum

valategrast — 2-(diethylamino)ethyl *N*-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzamido)-L-phenylalaninate

valatégrast — (2*S*)-2-[(2-chloro-6-méthylbenzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phényl]propanoate de 2-(diéthylamino)éthyle

valategrast — 2-(dietilamino)etil *N*-(2-cloro-6-metilbenzoil)-4-(2,6-diclorobenzamido)-L-fenilalaninato

$C_{30}H_{32}Cl_3N_3O_4$



valopicitabinum

valopicitabine — 3'-*O*-(L-valyl)-2'-*C*-methylcytidine

valopicitabine — 4-amino-1-[3-*O*-[(2*S*)-2-amino-3-méthylbutanoyl]-2-*C*-méthyl-β-D-ribofuranosyl]pyrimidin-2(1*H*)-one

valopicitabina — 3'-*O*-(L-valil)-2'-*C*-metilcitidina

$C_{15}H_{24}N_4O_6$



volociximabum

volociximab — immunoglobulin G4, anti-(human α5β1 integrin)(human-mouse clone p200-M heavy chain), disulfide with human-mouse clone p200-M κ-chain, dimer

volociximab — immunoglobuline G4, anti-(intégrine α5β1 humaine), dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal chimérique homme-souris p200-M

volociximab — inmunoglobulina G4, anti-(integrina α5β1 humana), dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal quimérico hombre-ratón p200-M

$C_{6434}H_{9942}N_{1706}O_{2040}S_{52}$

yttrium (^{90}Y) tacatuzumabum tetraxetanum

yttrium (^{90}Y) tacatuzumab tetraxetan

immunoglobulin G1, anti-(human α-fetoprotein) (human-mouse monoclonal hAFP-31 γ1-chain), disulfide with human-mouse monoclonal hAFP-31 κ-chain, dimer, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate, yttrium-^{90}Y chelate

yttrium (^{90}Y) tacatuzumab tétraxétan

chélate d'yttrium (^{90}Y) d'immunoglobuline G1, anti-(α-fétoprotéine humaine) ; dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal de souris humanisé hAFP-31 liée à l'acide 2,2',2'',2'''-(1,4,7,10-tétraazacyclododécane-1,4,7,10-tétryl)= tétraacétique par une fonction amide

ytrio (^{90}Y) tacatuzumab tetraxetán

quelato d'ytrio (^{90}Y) de la inmunoglobulina G1, anti-(α-fetoproteína humana) ; dímero del disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal de ratón humanizado hAFP-31 vinculada al ácido 2,2',2'',2'''-(1,4,7,10-tetraazaciclododecano-1,4,7,10-tetril)= tetraacetico por una función amida

$C_{6470}H_{9971}N_{1712}O_{2007}S_{42}{}^{90}Y$



zabofloxacinum

zabofloxacin

1-cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

zabofloxacine

acide 1-cyclopropyl-6-fluoro-7-[8-(méthoxyimino)-2,6-diazaspiro= [3.4]oct-6-yl]-4-oxo-1,4-dihydro-1,8-naphtyridine-3-carboxylique

zabofloxacino

ácido 1-ciclopropil-6-fluoro-7-[8-(metoxiimino)-2,6-diazaespiro= [3.4]octan-6-il]-4-oxo-1,4-dihidro-1,8-naftiridina-3-carboxílico

$C_{19}H_{20}FN_5O_4$



zalutumumabum

zalutumumab	immunoglobulin G1, anti-(human epidermal growth factor receptor)(human monoclonal 2F8 heavy chain), disulfide with human monoclonal 2F8 κ-chain, dimer
zalutumumab	immunoglobuline G1, anti-(récepteur du facteur de croissance épidermal humain), dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal humain 2F8
zalutumumab	inmunoglobulina G1, anti-(receptor del factor de crecimiento epidérmico humano), dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal humano 2F8

$C_{6512}H_{10074}N_{1734}O_{2032}S_{46}$

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 30
Dénominations communes internationales recommandées (DCI Rec.): Liste 30
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 30
(WHO Drug Information, Vol. 4, No. 3, 1990)

p. 2 **artesunatum**

artesunate	*insert the following graphic formula:*
artésunate	*insérer la formule graphique suivante:*
artesunato	*insertáse la fórmula desarollada por la siguiente:*



Recommended International Nonproprietary Names (Rec. INN): List 43
Dénominations communes internationales recommandées (DCI Rec.): Liste 43
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 43
(WHO Drug Information, Vol. 14, No. 1, 2000)

p. 70	*suprimase*	*insértese*
	tezosentano	tezosentán

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.